Balchem Corporation
- Jurisdiction
United States - LEI
549300VR70OPMHUI3557 - ISIN
US0576652004 (BCPC )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€95.25 28.5% overvalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€840.95M - Gross margin
35.8% - EBIT
€168.79M - EBIT margin
20.1% - Net income
€121.76M - Net margin
14.5%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
| N/A | N/A | |
| N/A | N/A |
Stock price
Dividends
- Last dividend amount
-
$0.87 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
19.8%
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Josh Gottheimer | May 14, 2025 | $1.00K–$15.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 3, 2024 (Q1 2024)